selected scholarly activity
-
conferences
- STEREOTACTIC BODY RADIATION THERAPY (SBRT) AND HYPO-FRACTIONATED RADIATION THERAPY (HFRT) OUTCOMES FOR LOW AND INTERMEDIATE-RISK PROSTATE CANCER (PRCA): EXPERIENCE AT TWO ONTARIO CENTRES. Radiotherapy and Oncology. S53-S53. 2023
- OUTCOMES OF RADIOTHERAPY ALONE FOR LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (LA-NSCLC) IN PATIENTS UNFIT FOR CHEMO-RADIOTHERAPY. Radiotherapy and Oncology. S39-S39. 2022
- RADIATION DOSE, TECHNIQUE, AND USE OF BRAIN RADIATION ON OVERALL SURVIVAL IN PATIENTS WITH LIMITED-STAGE SMALL CELL LUNG CANCER. Radiotherapy and Oncology. S31-S31. 2022
- RADIOTHERAPY DOSE, FDG-PET UTILIZATION AND SURVIVAL OUTCOMES OF UNRESECTED LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (LA-NSCLC). ONTARIO POPULATION OUTCOMES OF CONTEMPORARY RADIOTHERAPY ALONE AND STANDARD OF CARE CHEMO-RADIOTHERAPY. Radiotherapy and Oncology. S59-S60. 2022
- Contemporary outcomes of a systematic prostate cancer active surveillance program: Results from the Niagara Health System, Ontario, Canada.. Journal of Clinical Oncology. 241-241. 2022
- The Role of FDG-PET in Staging and Treatment for Stage III NSCLC in Ontario, Canada Between 2009-2017. International Journal of Radiation Oncology Biology Physics. e430-e430. 2021
- PROSTATE SBRT BOOST RADIOTHERAPY (PBS TRIAL): A RANDOMIZED PHASE II TRIAL OF SBRT VERSUS CONVENTIONALLY-FRACTIONATED RADIOTHERAPY BOOST FOLLOWING PELVIC RADIOTHERAPY IN HIGH-RISK PROSTATE CANCER. Radiotherapy and Oncology. S64-S64. 2021
- PSMA-PET-BASED RESPONSE ASSESSMENT OF METASTATIC PROSTATE CANCER RESPONSE TO RADIOTHERAPY: A CASE SERIES. Radiotherapy and Oncology. S11-S11. 2021
- THE ROLE OF FDG-PET IN STAGING AND TREATMENT FOR STAGE III NSCLC IN ONTARIO BETWEEN 2009-2017. Radiotherapy and Oncology. S44-S44. 2021
- Canagliflozin Mediates Effective Blockade of the mTORC1 - HIF-1a Pathway, Inhibits Growth and Enhances Non-Small Cell Lung Cancer (NSCLC) Response to Radiotherapy (RT). International Journal of Radiation Oncology Biology Physics. S56-S56. 2020
- Cardiac Toxicity in Central Non-Small Cell Lung Tumors treated with Stereotactic Body Radiation Therapy (SBRT) – Is there a “No-Flutter Zone”?. International Journal of Radiation Oncology Biology Physics. e138-e138. 2020
- Impact of Pelvic Intensity-modulated Radiotherapy (IMRT) on Lymph Node Coverage and Dose to Critical Organs, Compare to Three-Dimensional Conformal Radiation Therapy (3D-CRT), in Localized High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics. e250-e250. 2020
- Randomized Phase II Trial of Metformin in Combination with Chemoradiotherapy (CRT) in Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC); the OCOG-ALMERA trial (NCT02115464). International Journal of Radiation Oncology Biology Physics. S104-S104. 2020
- A RANDOMIZED PHASE II TRIAL OF PROSTATE BOOST IRRADIATION WITH STEREOTACTIC BODY RADIOTHERAPY (SBRT) IN HIGH-RISK PROSTATE CANCER. THE PBS TRIAL. Radiotherapy and Oncology. S87-S88. 2020
- CARDIAC TOXICITY IN CENTRAL NON-SMALL CELL LUNG TUMOURS TREATED WITH STEREOTACTIC BODY RADATION THERAPY (SBRT) - IS THERE A "NO-FLUTTER ZONE"?. Radiotherapy and Oncology. S83-S83. 2020
- CANAGLIFLOZIN, A NEW ANTI-DIABETIC AGENT TARGETING CELLULAR METABOLISM, SUPPRESSES SURVIVAL AND ENHANCES THE RESPONSE OF NON-SMALL CELL LUNG CANCER (NSCLC) TO RADIOTHERAPY. Radiotherapy and Oncology. S20-S20. 2019
- IMPACT OF PELVIC INTENSITY-MODULATED RADIOTHERAPY (IMRT) ON LYMPH NODE COVERAGE AND DOSE TO CRITICAL ORGANS, COMPARE TO THREE-DIMENSIONAL CONFORMAL RADIATION THERAPY (3D-CRT), IN LOCALIZED HIGH-RISK PROSTATE CANCER. Radiotherapy and Oncology. S68-S68. 2019
- OA12.03 Initial Reporting of NRG-LU001, Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC. Journal of Thoracic Oncology. S237-S238. 2019
- P1.14-33 Canagliflozin Inhibits Lung Cancer Survival and Enhances Its Response to Radiotherapy; Effective Blockade of mTOR Pathway, HIF1a, and Mitosis. Journal of Thoracic Oncology. S566-S567. 2019
- THE NEW DIABETES DRUG CANAGLIFLOZIN ENHANCES THE RESPONSE OF PROSTATE CANCER TO RADIOTHERAPY. Radiotherapy and Oncology. S71-S72. 2019
- Initial reporting of NRG-LU001 (NCT02186847), randomized phase II trial of concurrent chemoradiotherapy (CRT) plus /- metformin in locally advanced Non-Small Cell Lung Cancer (NSCLC).. Journal of Clinical Oncology. 2019
- Lung SBRT Credentialing in the Canadian LUSTRE Randomized Trial. International Journal of Radiation Oncology Biology Physics. S235-S235. 2018
- Outcomes of Stereotactic Body Radiation Therapy for Abdominopelvic Oligometastases. International Journal of Radiation Oncology Biology Physics. e67-e68. 2018
- 127TiP Phase I study of neo-adjuvant Stereotactic Body Radiotherapy (SBRT) in operable patients with borderline resectable locally advanced NSCLC (LA-NSCLC) (LINNEARRE I STUDY: NCT02433574). Journal of Thoracic Oncology. S70-S71. 2018
- 69P The diabetes drug canagliflozin sensitizes non-small cell lung cancer (NSCLC) to radiotherapy and chemotherapy. Journal of Thoracic Oncology. S37-S37. 2018
- A Phase 3, Multicenter, Randomized Trial to Evaluate the Symptomatic and Quality of Life Improvements in Lung Cancer Patients Receiving External Beam Radiation With or Without High Dose Rate Intraluminal Brachytherapy. International Journal of Radiation Oncology Biology Physics. S116-S116. 2017
- Comparison of Fiducial Marker Implantation and Soft Tissue Registration Using Cone Beam CT in Image-Guided Radiation Therapy of the Prostate. International Journal of Radiation Oncology Biology Physics. E722-E722. 2017
- Randomized Study of Quality of Life in Patients with High-Risk Prostate Cancer Undergoing Radiotherapy: Role of Pelvic Nodal IMRT. International Journal of Radiation Oncology Biology Physics. E211-E212. 2017
- COMBINED SALICYLATE (SAL) - METFORMIN (MET) TREATMENT INDUCES INCREASED TUMOUR SUPPRESSION AND RADIOSENSITIZATION IN PRECLINICAL MODELS OF PROSTATE CANCER (PRCA). Radiotherapy and Oncology. S35-S35. 2016
- PHASE I STUDY OF NEO-ADJUVANT STEREOTACTIC BODY RADIOTHERAPY (SBRT) IN OPERABLE PATIENTS WITH BORDERLINE RESECTABLE LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (LA- NSCLC) (LINNEARRE I STUDY: NCT02433574). Radiotherapy and Oncology. S58-S59. 2016
- Metabolic stress to sensitize non-small cell lung cancer (NSCLC) to radiotherapy: Studies from bench to bedside. Journal of Thoracic Oncology. S91-S91. 2016
- NRG-LU001: A phase II trial investigating metformin as a chemo-radio-sensitizer in locally advanced non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. S49-S50. 2016
- OCOG-ALMERA: A phase II trial investigating the ability of metformin to chemo-radio-sensitize and prevent recurrence in locally advanced (LA) non-small cell lung cancer (NSCLC)∗. Journal of Thoracic Oncology. S50-S51. 2016
- Targeting tumor metabolism to improve radio-sensitivity in non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. S50-S50. 2016
- Early Results of a Quality Assurance Program in a Randomized Trial of Stereotactic Body Radiotherapy for Stage I Medically Inoperable Lung Cancer. Journal of Thoracic Oncology. S327-S327. 2015
- Pulmonary Function Test and Its Predictive Factors in Patients With Lung Malignancies Treated With Stereotactic Radiation Therapy: A Retrospective Review From a Single Institution. International Journal of Radiation Oncology Biology Physics. S550-S550. 2013
- THE ANTI-DIABETIC DRUG METFORMIN SENSITIZES HUMAN NON-SMALL CELL LUNG CANCER (NSCLC) XENOGRAFTS TO IONIZING RADIATION.. Journal of Thoracic Oncology. S571-S572. 2011
- A randomized phase III trial of magic mouthwash and sucralfate versus benzydamine hydrochloride for prophylaxis of radiation-induced oral mucositis in head and neck cancer.. Journal of Clinical Oncology. 5521-5521. 2011
- Abstract 2491: Metformin sensitizes human lung cancer xenografts to ionizing radiation: Response of the AMPK pathway. Cancer Research. 2491-2491. 2011
- Abstract 4071: Sestrins modulate the expression of the metabolic stress sensor AMPK in breast cancer cells. Cancer Research. 4071-4071. 2011
- 110 ACTIVATORS OF AMP-ACTIVATED PROTEIN KINASE (AMPK) ENHANCE RADIATION RESPONSES IN LUNG CANCER CELLS. Radiotherapy and Oncology. S35-S35. 2009
- 46 IONIZING RADIATION ACTIVATES AMP – ACTIVATED PROTEIN KINASE (AMPK) IN HUMAN EPITHELIAL TUMOUR CELLS THROUGH AN LKB1-INDEPENDENT AND ATM-DEPENDENT PATHWAY. Radiotherapy and Oncology. S15-S15. 2009
- ACUTE URINARY MORBIDITY OF RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER: DO PATIENTS UNDERGOING CONFORMAL RADIATION THERAPY WITH IMPLANTED GOLD SEEDS HAVE MORE URINARY SYMPTOMS DURING RADIATION THERAPY?. Radiotherapy and Oncology. S52-S53. 2008
- IMPACT OF BLADDER FILLING (FULL OR EMPTY) ON DOSE VOLUME HISTOGRAMS IN RADIATION PLANNING FOR POST-PROSTATECTOMY PATIENTS. Radiotherapy and Oncology. S54-S54. 2008
- INFLUENCE OF GOLD SEED IMPLANTATION ON DEFINING TARGET VOLUMES FOR CONFORMAL RADIOTHERAPY OF PROSTATE CANCER. Radiotherapy and Oncology. S51-S51. 2008
- INVESTIGATING RESVERATROL IN COMBINATION WITH RADIATION IN PROSTATE CANCER. Radiotherapy and Oncology. S37-S37. 2008
- Influence of Gold Seed Implantation on Defining Target Volumes for Conformal Radiotherapy of Prostate Cancer. International Journal of Radiation Oncology Biology Physics. S322-S322. 2008
- Plasma membrane and cytoplasmic activated EGF receptor predicts survival and cytoplasmic activated Erk predicts tumour response in locally advanced NSCLC patients treated with chemo-radiotherapy. Radiotherapy and Oncology. S57-S57. 2007
- P-126 Activation of tyrosine kinase receptors and intracellular signal mediators in NSCLC tumors. Lung Cancer. S148-S148. 2005
- Mitogen-activated protein kinase (MAPK) expression and activation in non-small cell lung cancer (NSCLC): Investigating their prognostic significance and role in radiation responses.. Radiotherapy and Oncology. S40-S41. 2004
- Alternative pathways of MAP kinase activation by tyrosine kinase receptors.. The FASEB Journal. A194-A194. 1998
- Involvement of the actin network in insulin signalling.. Society of General Physiologists Series. 257-271. 1997
-
journal articles
- Salsalate improves the anti-tumor efficacy of lenvatinib in MASH-driven hepatocellular carcinoma.. JHEP Reports. 7:101354. 2025
- Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration resistant prostate cancer: A randomized phase II trial (GROUQ-PCS 9).. Journal of Clinical Oncology. 43:22-22. 2025
- OCOG-RATIONAL: A phase II randomized trial of optimal recurrence-directed therapy (RDT) without or with androgen-deprivation therapy (ADT) in radio-recurrent oligo-metastatic castrate sensitive prostate cancer (romCSPC).. Journal of Clinical Oncology. 43:TPS305-TPS305. 2025
- Patterns of failure with 18F-DCFPyL PSMA-PET/CT in the post-prostatectomy setting A regional cohort analysis.. Journal of the Canadian Urological Association. 19:17-24. 2025
- Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy.. Radiation Oncology. 19:155. 2024
- Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer: The LUSTRE Phase 3 Randomized Clinical Trial.. JAMA Oncology. 10:1571-1575. 2024
- EP.08B.03 Prognostic Value of Irradiated Cardiac and Metabolic Tumor Volume in Unresected LA-NSCLC Treated with Concurrent Chemo-Radiotherapy.. Journal of Thoracic Oncology. 19:s566. 2024
- Forecasted Global Brachytherapy Shortfall by 2040: Investments Needed to Overcome this Deficit. International Journal of Radiation Oncology Biology Physics. 120:E754-E755. 2024
- Geographical Disparities in Access to Radiotherapy in Brazil: An Observational Study. International Journal of Radiation Oncology Biology Physics. 120:E22-E23. 2024
- MA01.07 Long-Term Analysis of NRG-LU001, Randomized Phase II Trial of Concurrent Chemoradiotherapy (ccrt) -/+ Metformin in Locally Advanced NSCLC.. Journal of Thoracic Oncology. 19:s53-s54. 2024
- MA14.07 Access Disparities to Lung Cancer Radiotherapy Across Brazil: An Observational Analysis. Journal of Thoracic Oncology. 19:s112. 2024
- Stereotactic Body Radiotherapy (SBRT) vs. Conventional Fractionation External Beam Radiotherapy (EBRT) Boost for Unfavorable Intermediate and High-Risk Prostate Cancer; Early Results of PBS: A Phase II Randomized Trial (NCT03380806). International Journal of Radiation Oncology Biology Physics. 120:S126-S127. 2024
- 102 Inequity and the Traveled Distance to Receive Radiotherapy in Brazil: A Cohort Study. Radiotherapy and Oncology. 198:s46. 2024
- 124 Phase II Randomized Trial of Optimal Recurrence-Directed Therapy (RDT) Without or with Androgen-Deprivation Therapy (ADT) in Radio-Recurrent Oligo-Metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC): The OCOG-Rational-PCS Trial. Radiotherapy and Oncology. 198:s54-s55. 2024
- 181 The Projected Global Shortage of Brachytherapy by 2040: Required Investments to Address the Shortfall. Radiotherapy and Oncology. 198:s76-s77. 2024
- 23 Stereotactic Body Versus Conventional Fractionation External Beam Radiotherapy (EBRT) Boost for High-Risk Prostate Cancer (HR-PC); Early Results of PBS: A Phase II Randomized Trial (NCT03380806). Radiotherapy and Oncology. 198:s13-s14. 2024
- Meta-Analysis of Stereotactic Body Radiation ThERapy in Nonspine BONE Metastases (MASTER-BONES). International Journal of Radiation Oncology Biology Physics. 119:1403-1412. 2024
- Stereotactic ablative radiotherapy for locally advanced non-small cell lung cancer: A systematic review and meta-analysis. Radiotherapy and Oncology. 201:110439-110439. 2024
- Disease control outcomes of stereotactic body radiation therapy or moderate hypo‐fractionation for prostate cancer: Real‐world experience at two Canadian centers. Prostate. 84:193-202. 2024
- Prostate-Specific Membrane Antigen (PSMA) Expression Predicts Need for Early Treatment in Prostate Cancer Patients Managed with Active Surveillance. International Journal of Molecular Sciences. 24:16022-16022. 2023
- Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α. Molecular Oncology. 17:2235-2256. 2023
- Circulating Growth Differentiation Factor 15 as a Biomarker in Patients with Unresected Locally Advanced Non-Small Cell Lung Cancer Treated with Chemo-Radiotherapy with or without Metformin. International Journal of Radiation Oncology Biology Physics. 117:e14-e15. 2023
- Progression-Free Survival as a Surrogate Endpoint of Overall Survival in Patients with Locally Advanced Non-Small Cell Lung Cancer Treated with Chemoradiotherapy: Trial-Level Meta-Analysis and Individual-Level Analysis of NRG/RTOG 0617 and PROCLAIM. International Journal of Radiation Oncology Biology Physics. 117:S128-S128. 2023
- The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy. Communications Biology. 6:919. 2023
- 114 Stereotactic Body Radiation Therapy (SBRT) and Hypo-Fractionated Radiation Therapy (HFRT) Outcomes for Low and Intermediate-Risk Prostate Cancer (PRCA): Experience at Two Ontario Centres. Radiotherapy and Oncology. 186:S53-S53. 2023
- Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice. Cell Reports Medicine. 4:101193-101193. 2023
- GDF15 promotes weight loss by enhancing energy expenditure in muscle. Nature. 619:143-150. 2023
- BRACHY: A Randomized Trial to Evaluate Symptom Improvement in Advanced Non-Small Cell Lung Cancer Treated With External Beam Radiation With or Without High-Dose-Rate Intraluminal Brachytherapy. International Journal of Radiation Oncology Biology Physics. 116:601-610. 2023
- 18F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer. Clinical and Translational Radiation Oncology. 39:100583-100583. 2023
- Biochemical disease control outcomes of stereotactic body radiation therapy (SBRT) or moderate hypo-fractionation (HFRT) for low- and intermediate-risk prostate cancer (PrCa): Retrospective analysis of 12 years of experience at two Canadian cancer centers.. Journal of Clinical Oncology. 41:363-363. 2023
- Patterns of failure after radiotherapy (RT) in patients with prostate cancer re-staged with 18F-DCFPyL PSMA-PET: A regional cohort analysis.. Journal of Clinical Oncology. 41:45-45. 2023
- Patterns of failure with 18F-DCFPyL PSMA PET/CT in the post-prostatectomy setting: A regional cohort analysis.. Journal of Clinical Oncology. 41:309-309. 2023
- Contemporary real-world radiotherapy outcomes of unresected locally advanced non-small cell lung cancer. Journal of Thoracic Disease. 15:423-433. 2023
- The impact of staging FDG-PET/CT on treatment for stage III NSCLC - an analysis of population-based data from Ontario, Canada. Frontiers in Oncology. 13:1210945. 2023
- LUSTRE: A Phase III Randomized Trial of Stereotactic Body Radiotherapy (SBRT) vs. Conventionally Hypofractionated Radiotherapy (CRT) for Medically Inoperable Stage I Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology Biology Physics. 114:1061-1062. 2022
- Lung SBRT credentialing in the Canadian OCOG-LUSTRE randomized trial. Clinical and Translational Radiation Oncology. 37:145-152. 2022
- Radiation Dose, Technique and Use of Brain Radiation on Overall Survival in Patients with Limited-Stage Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics. 114:e411-e411. 2022
- Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. The Lancet Oncology. 23:1308-1320. 2022
- 139: Radiotherapy Dose, FDG-PET Utilization and Survival Outcomes of Unresected Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC). Ontario Population Outcomes of Contemporary Radiotherapy Alone and Standard of Care Chemo-Radiotherapy. Radiotherapy and Oncology. 174:S59-S60. 2022
- 68: Radiation Dose, Technique, and Use of Brain Radiation on Overall Survival in Patients with Limited-Stage Small Cell Lung Cancer. Radiotherapy and Oncology. 174:S31-S31. 2022
- 88: Outcomes of Radiotherapy Alone for Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) in Patients Unfit for Chemo-Radiotherapy. Radiotherapy and Oncology. 174:S39-S39. 2022
-
Salvage radiotherapy following
HiFU : An institutional series and literature review. Journal of Medical Imaging and Radiation Oncology. 66:847-852. 2022 - Metformin-induced reductions in tumor growth involves modulation of the gut microbiome. Molecular Metabolism. 61:101498-101498. 2022
- Metformin—A Thought-provoking Addition to Anticancer Therapies—Reply. JAMA Oncology. 8:303-303. 2022
- The Journey of Radiotherapy Dose Escalation in High Risk Prostate Cancer; Conventional Dose Escalation to Stereotactic Body Radiotherapy (SBRT) Boost Treatments. Clinical Genitourinary Cancer. 20:e25-e38. 2022
- Combined metformin-salicylate treatment provides improved anti-tumor activity and enhanced radiotherapy response in prostate cancer; drug synergy at clinically relevant doses. Translational Oncology. 14:101209-101209. 2021
- 100: The Role of FDG-PET in Staging and Treatment for Stage III NSCLC in Ontario between 2009-2017. Radiotherapy and Oncology. 163:S44-S44. 2021
- 151: Prostate SBRT Boost Radiotherapy (PBS Trial): A Randomized Phase II Trial of SBRT Versus Conventionally-Fractionated Radiotherapy Boost Following Pelvic Radiotherapy in High-Risk Prostate Cancer. Radiotherapy and Oncology. 163:S64-S64. 2021
- 18: PSMA-PET-Based Response Assessment of Metastatic Prostate Cancer Response to Radiotherapy: A Case Series. Radiotherapy and Oncology. 163:S11-S11. 2021
- Tyrosine Kinase Inhibitor Therapy in Unresectable Locally Advanced NSCLC: Keep Holding Our Breaths or Time to Take a Breather?. Journal of Thoracic Oncology. 16:1607-1609. 2021
- Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Non–Small Cell Lung Cancer. JAMA Oncology. 7:1324-1324. 2021
- Metformin in Combination With Chemoradiotherapy in Locally Advanced Non–Small Cell Lung Cancer. JAMA Oncology. 7:1333-1333. 2021
- Radiographic and metabolic evolution of prostate cancer lung metastasis detected by prostate-specific membrane antigen and fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography. World Journal of Nuclear Medicine. 19:421-424. 2020
- 194: Cardiac Toxicity in Central Non-Small Cell Lung Tumours Treated with Stereotactic Body Radation Therapy (SBRT) - Is There A “No-Flutter Zone”?. Radiotherapy and Oncology. 150:S83-S83. 2020
- 206: A Randomized Phase Ii Trial of Prostate Boost Irradiation with Stereotactic Body Radiotherapy (SBRT) in High-Risk Prostate Cancer. The Pbs Trial. Radiotherapy and Oncology. 150:S87-S88. 2020
- A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: The PBS Trial (NCT03380806). Clinical Genitourinary Cancer. 18:e410-e415. 2020
- Overall and chemotherapy‐free survival following stereotactic body radiation therapy for abdominopelvic oligometastases. Journal of Medical Imaging and Radiation Oncology. 64:563-569. 2020
- Summary of international recommendations in 23 languages for patients with cancer during the COVID-19 pandemic. The Lancet Oncology. 21:759-760. 2020
- Patient and family support in the era of fake e-medicine: food for thought from an international consensus panel. ESMO Open. 5:e000696-e000696. 2020
- Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. The Lancet Oncology. 20:1531-1543. 2019
- 158 Impact of Pelvic Intensity-Modulated Radiotherapy (IMRT) on Lymph Node Coverage and Dose to Critical Organs, Compare to Three-Dimensional Conformal Radiation Therapy (3D-CRT), in Localized High-Risk Prostate Cancer. Radiotherapy and Oncology. 139:S68-S68. 2019
- 167 The New Diabetes Drug Canagliflozin Enhances the Response of Prostate Cancer to Radiotherapy. Radiotherapy and Oncology. 139:S71-S72. 2019
- 40 Canagliflozin, a New Anti-Diabetic Agent Targeting Cellular Metabolism, Suppresses Survival and Enhances the Response of Non-Small Cell Lung Cancer (NSCLC) to Radiotherapy. Radiotherapy and Oncology. 139:S20-S20. 2019
- Initial reporting of NRG-LU001 (NCT02186847), randomized phase II trial of concurrent chemoradiotherapy (CRT) +/- metformin in locally advanced Non-Small Cell Lung Cancer (NSCLC).. Journal of Clinical Oncology. 37:8502-8502. 2019
- Salicylate enhances the response of prostate cancer to radiotherapy. Prostate. 79:489-497. 2019
- Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma. Cell Metabolism. 29:174-182.e5. 2019
- Mechanisms of Metformin on Colon Cancer Inhibition: Roles of the Gut Microbiome, Butyrate and AMPK. Canadian Journal of Diabetes. 42:S2-S2. 2018
-
AMPK β1 reduces tumor progression and improves survival in p53 null mice. Molecular Oncology. 11:1143-1155. 2017 - Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials. Oncotarget. 8:57733-57754. 2017
- Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials.. Oncotarget. 8:57733-57754. 2017
- A Novel Neoadjuvant Therapy for Operable Locally Invasive Non–Small-Cell Lung Cancer. Phase I Study of Neoadjuvant Stereotactic Body Radiotherapy. LINNEARRE I (NCT02433574). Clinical Lung Cancer. 18:436-440.e1. 2017
- Abstract 5850: Salicylate sensitizes prostate cancer (PrCa) to radiotherapy; activation of AMPK and suppression of lipogenesis. Cancer Research. 77:5850-5850. 2017
- Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. Journal of Clinical Oncology. 35:1884-1890. 2017
- Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non–Small-Cell Lung Cancer – Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial. Clinical Lung Cancer. 18:250-254. 2017
- The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration. Molecular Metabolism. 5:1048-1056. 2016
- 159: Phase I Study of NEO-Adjuvant Stereotactic Body Radiotherapy (SBRT) in Operable Patients with Borderline Resectable Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) (Linnearre I Study: NCT02433574). Radiotherapy and Oncology. 120:S58-S59. 2016
- 90: Combined Salicylate (SAL) - Metformin (MET) Treatment Induces Increased Tumour Suppression and Radiosensitization in Preclinical Models of Prostate Cancer (PRCA). Radiotherapy and Oncology. 120:S35-S35. 2016
- Metformin for chemo-radio-sensitization of NSCLC. Radiotherapy and Oncology. 120:363-364. 2016
- 84P Metabolic stress to sensitize non-small cell lung cancer (NSCLC) to radiotherapy: Studies from bench to bedside. Journal of Thoracic Oncology. 11:S91-S91. 2016
- A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation for Patients With Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 17:142-149. 2016
- Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment. Metabolism: Clinical and Experimental. 65:124-139. 2016
- Salicylate activates AMPK and synergizes with metformin to reduce the survival of prostate and lung cancer cells ex vivo through inhibition of de novo lipogenesis. Biochemical Journal. 469:177-187. 2015
- Increased skeletal muscle glucose uptake by rosemary extract through AMPK activation. Applied Physiology, Nutrition and Metabolism. 40:407-413. 2015
- Inhibition of human lung cancer cell proliferation and survival by wine. Cancer Cell International. 14:6. 2014
- AMP-activated protein kinase (AMPK) beyond metabolism. Cancer Biology and Therapy. 15:156-169. 2014
- Predicting 2-Year Survival for Radiation Regimens in Advanced Non-small Cell Lung Cancer. Clinical Oncology. 25:697-705. 2013
- Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. British Journal of Cancer. 108:2021-2032. 2013
- Chronic modulation of AMP-Kinase, Akt and mTOR pathways by ionizing radiation in human lung cancer xenografts. Radiation Oncology. 7:71. 2012
- Expression of the glucose transporters GLUT1, GLUT3, GLUT4 and GLUT12 in human cancer cells. BMC Proceedings. 6:p4. 2012
- Ionizing radiation regulates the expression of AMP-activated protein kinase (AMPK) in epithelial cancer cells. Radiotherapy and Oncology. 102:459-465. 2012
- Sestrin2 Modulates AMPK Subunit Expression and Its Response to Ionizing Radiation in Breast Cancer Cells. PLoS ONE. 7:e32035-e32035. 2012
- Establishing a relationship between prolactin and altered fatty acid β-Oxidation via carnitine palmitoyl transferase 1 in breast cancer cells. BMC Cancer. 11:56. 2011
- Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways. Radiation Oncology. 6:144. 2011
- Lovastatin Sensitizes Lung Cancer Cells to Ionizing Radiation: Modulation of Molecular Pathways of Radioresistance and Tumor Suppression. Journal of Thoracic Oncology. 6:439-450. 2011
- Ionizing Radiation Activates AMP-Activated Kinase (AMPK): A Target for Radiosensitization of Human Cancer Cells. International Journal of Radiation Oncology Biology Physics. 78:221-229. 2010
- Association of Phosphorylated Epidermal Growth Factor Receptor with Survival in Patients with Locally Advanced Non-small Cell Lung Cancer Treated with Radiotherapy. Journal of Thoracic Oncology. 3:716-722. 2008
- P-125 p-38 MAPK, Erk and Akt expression and activation in NSCLCtumors; Subcellular distribution and radiographic response to radiotherapy. Lung Cancer. 49:S147-S148. 2005
- Insulin, Insulin-like Growth Factor-I, and Platelet-Derived Growth Factor Activate Extracellular Signal-Regulated Kinase by Distinct Pathways in Muscle Cells. Biochemical and Biophysical Research Communications. 288:205-211. 2001
- Role of the actin cytoskeleton in insulin action. Microscopy Research and Technique. 47:79-92. 1999
- Actin filaments participate in the relocalization of phosphatidylinositol 3-kinase to glucose transporter containing compartments and in the stimulation of glucose uptake in 3T3-L1 adipocytes. Biochemical Journal. 341:861-863. 1999
- Actin filaments participate in the relocalization of phosphatidylinositol 3-kinase to glucose transporter containing compartments and in the stimulation of glucose uptake in 3T3-L1 adipocytes (vol 331, pg 917, 1998). Biochemical Journal. 341:861-861. 1999
- Rapid stimulation of glucose transport by mitochondrial uncoupling depends in part on cytosolic Ca2+ and cPKC. American Journal of Physiology. 275:C1487-C1497. 1998
- Actin Filaments Facilitate Insulin Activation of the Src and Collagen Homologous/Mitogen-activated Protein Kinase Pathway Leading to DNA Synthesis and c-fos Expression. Journal of Biological Chemistry. 273:28322-28331. 1998
- Actin filaments participate in the relocalization of phosphatidylinositol 3-kinase to glucose-transporter-containing compartments and in the stimulation of glucose uptake in 3T3-L1 adipocytes. Biochemical Journal. 333:847-848. 1998
- Correction: Actin filaments participate in the relocalization of phosphatidylinositol 3-kinase to glucose-transporter-containing compartments and in the stimulation of glucose uptake in 3T3-L1 adipocytes (Biochemical Journal (1998) 331 (917-928)). Biochemical Journal. 333:848. 1998
- Actin filaments participate in the relocalization of phosphatidylinositol3-kinase to glucose transporter-containing compartments and in the stimulation of glucose uptake in 3T3-L1 adipocytes. Biochemical Journal. 331:917-928. 1998
- Glucose transporter expression in L6 muscle cells: Regulation through insulin- and stress-activated pathways. American Journal of Physiology. 273:E68-E76. 1997
- Stimulation of Glucose Uptake by the Natural Coenzyme α-Lipoic Acid/Thioctic Acid: Participation of Elements of the Insulin Signaling Pathway. Diabetes. 45:1798-1804. 1996
- Insulin Activates a p21-activated Kinase in Muscle Cells via Phosphatidylinositol 3-Kinase. Journal of Biological Chemistry. 271:19664-19667. 1996
- The glucose transporters of skeletal muscle. Seminars in Cell and Developmental Biology. 7:229-237. 1996
- Exercise increases the plasma membrane content of the Na+ -K+ pump and its mRNA in rat skeletal muscles. Journal of applied physiology. 80:699-705. 1996
- Multiple roles of phosphatidylinositol 3-kinase in regulation of glucose transport, amino acid transport, and glucose transporters in L6 skeletal muscle cells. Endocrinology. 136:4315-4322. 1995
- Multiple roles of phosphatidylinositol 3-kinase in regulation of glucose transport, amino acid transport, and glucose transporters in L6 skeletal muscle cells.. Endocrinology. 136:4315-4322. 1995
- Phosphatidylinositol 3-kinase and the actin network are not required for the stimulation of glucose transport caused by mitochondrial uncoupling: comparison with insulin action. Biochemical Journal. 309:1-5. 1995
- Disassembly of the actin network inhibits insulin-dependent stimulation of glucose transport and prevents recruitment of glucose transporters to the plasma membrane.. Journal of Biological Chemistry. 269:29934-29942. 1994
- Structural disruption of the trans-Golgi network does not interfere with the acute stimulation of glucose and amino acid uptake by insulin-like growth factor I in muscle cells. Biochemical Journal. 297:289-295. 1994
- Regulation of expression of glucose transporters by glucose: a review of studies in vivo and in cell cultures. The FASEB Journal. 8:43-53. 1994
-
preprints